Showing results (1351-1360 of 1,689) with videos related to
Sort By:
Pageof 169
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2012
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchLeena V Maramattom, Parameswaran N Hari, Linda J Burns, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2013
Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphomaSonali M Smith, Linda J Burns, Koen van Besien, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modalityTimothy S Fenske, Mei-Jie Zhang, Jeanette Carreras, et al.Thrombosis and Haemostasis|June 30, 2019
Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C DeficiencyLaura Martos, Álvaro Fernández-Pardo, María F López-Fernández, et al.Cancer|July 28, 2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapyNarendranath Epperla, Kami J Maddocks, Mohammed Salhab, et al.American Journal of Physiology. Heart and Circulatory Physiology|March 9, 2026
Guidelines for Evaluating Endothelial Function in Vascular TissueCameron G McCarthy, Christian Aalkjær, Pooneh Bagher, et al.American Journal of Hematology|November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapiesLuciano J Costa, Kami Maddocks, Narendranath Epperla, et al.The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.British Journal of Cancer|July 2, 2025
Chemotherapy-induced neuropathy in monomethyl Auristatin E treatment: prevention by lithiumMatheus F Itaborahy, Isadora Z L F Feng, Uri F Vieira-Machado, et al.Pageof 169